Royalty Report: Cancer, Drugs, Radiation – Collection: 372929

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Cancer
  • Drugs
  • Radiation
  • Medical
  • Therapeutic
  • Pharmaceuticals
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372929

License Grant
Licensor granted to the Licensee of the Cayman Islands an exclusive license under certain patents and know-how of Licensor to develop and commercialize Licensor’s proprietary product NBTXR3 in the territory of Mainland China, Macau, Hong Kong, Thailand, Taiwan, South Korea and Singapore, in the licensed field of use of a product activated by radiotherapy in oncology. Licensee will participate in a global phase III registrational study in head and neck cancer for the licensed product and four additional registrational studies across indications and therapeutic combinations. We are obligated to use commercially reasonable efforts to enroll a certain percentage of study patients in the territory in such studies.
License Property
NBTXR3, a radiosensitizer designed to be injected directly into a malignant tumor prior to standard radiotherapy. When exposed to ionizing radiation, NBTXR3 has been shown to enhance the localized effect of radiotherapy. NBTXR3 is designed to enhance the effect of radiotherapy without resulting in additional side effects on surrounding healthy tissue. NBTXR3 may also prime the body’s immune response against cancer, and clinical activity has been observed across a number of different solid tumor types and in combination with immuno-oncology agents. Clinical proof of concept for NBTXR3 has been demonstrated in soft tissue sarcoma.
Field of Use
Field of Use is for radiotherapy treatment in oncology.

IPSCIO Record ID: 370599

License Grant
Licensee from Cayman Islands obtained an exclusive, sublicensable license under certain patents and know-how of Licensor to develop, manufacture, use, sell, import and commercialize Licensor’s proprietary SHP2 inhibitor, BBP-398 (formerly known as IACS-15509) in the licensed territory of Mainland China, Hong Kong, Macau, Taiwan, Thailand, Singapore, and South Korea, in the licensed field of diagnostic, prophylactic, palliative, and therapeutic uses or indications in humans.
License Property
SHP2 inhibitor (BBP-398) (formerly known as IACS-15509) is an orally available allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK-mediated MAPK signal transduction pathway.
Field of Use
Licensed field is for diagnostic, prophylactic, palliative, and therapeutic uses or indications in humans including for the potential treatment of MAPK-driven solid tumors.

MAPK (mitogen-activated protein kinase) pathway is a central axis driving aberrant proliferation in a broad spectrum of cancers.

IPSCIO Record ID: 365586

License Grant
Licensee of Israel acquired certain intellectual property for research and development activities relating to the alpha radiation products from the University.
License Property
Alpha radiation products consist of but not limited to the Alpha DaRT technology that is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range. The Alpha DaRT source is directly inserted into the tumor and is designed to release radiation with a high-linear energy transfer over a range of a few millimeters, potentially sparing the surrounding healthy tissue. It was evaluated that the feasibility, safety and efficacy of the Alpha DaRT technology in a first-in-human study of locally advanced and recurrent squamous cell carcinoma, or SCC, cancers of the skin and head and neck.
Field of Use
Field of use is for treatment of Cancer utilizing radiation therapy.

IPSCIO Record ID: 276397

License Grant
Licensee obtains rights in mainland China, Hong Kong, Macau and Taiwan to develop and commercialize enoblituzumab.
License Property
Enoblituzumab is an investigational, Fc-optimized mAb that targets B7-H3. MacroGenics recently met with FDA to discuss its plans regarding a Phase 2/3 registration-directed study of enoblituzumab in combination with MGA012 in patients with squamous cell carcinoma of the head and neck (SCCHN).

A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 366038

License Grant
Licensee of Israel acquired certain intellectual property for research and development activities relating to the alpha radiation products from the Israelis University.
License Property
Alpha radiation products consist of but not limited to the Alpha DaRT technology that is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range. The Alpha DaRT source is directly inserted into the tumor and is designed to release radiation with a high-linear energy transfer over a range of a few millimeters, potentially sparing the surrounding healthy tissue. It was evaluated that the feasibility, safety and efficacy of the Alpha DaRT technology in a first-in-human study of locally advanced and recurrent squamous cell carcinoma, or SCC, cancers of the skin and head and neck.
Field of Use
Field of use is for treatment of Cancer utilizing radiation therapy.

IPSCIO Record ID: 282869

License Grant
Licensor shall grant the Swiss Licensee the right with respect to the Products to exercise an option to obtain a sole and exclusive license, including the right to grant sublicenses, under the Licensor Patent Rights and Joint Patent Rights, and a nonexclusive license to use the Licensor Know-How, in each case solely to make, use, offer for sale, sell and import the Products in the Territory for use in the Field.

Licensee shall have, with respect to such designated Optioned Compound and its associated Products, for no further consideration, a sole and exclusive license, including the right to grant sub-licenses, under the Licensor Patent Rights, and a nonexclusive license to use the Licensor Know-How, in each case solely to make, use, offer for sale, sell and import such product in the Territory for use outside the Field, except that such licenses shall exclude Specifically Excluded Areas.

License Property
Licensor technology is for the treatment of oncological diseases based on E2F1 technology and associated compounds, the Licensors Program, and owns related intellectual property rights.

Product means any and all products for use in the Field that include, in whole or as a component thereof, an Optioned Compound.

Patents are related, but not limited to, Treatment of Human Prostate Disease, and, Method of treating Hematologic Tumors and Cancers.

Optioned Compounds means the Primary Compound, the Clinical Candidates and, if Licensee makes the payment required, then also the Potential Optioned Compounds.

Backup Compound means, as of the Option Exercise, any analog of the Primary Compound and any other compound developed by Licensor that has been screened for regulation of the E2F1 protein prior to the Effective Date or as part of the Strategic Alliance, and as a direct result of such screening has been determined to modulate E2F1 in cancer cells, directly leading to apoptosis.

Field of Use
Field means only all Indications. For the avoidance of doubt, the Field does not include Specifically Excluded Areas.

Specifically Excluded Areas means the protection or treatment of normal cells against all forms of radiation including ionizing and non-ionizing radiation (including but not limited to radiotherapy), including protection of normal cells against cancer induced by any form of radiation, and the use of a compound in stents.

IPSCIO Record ID: 1054

License Grant
Licensor hereby grants an exclusive, non-transferable, sublicensable right and license, solely in the Licensed Territory and the Licensed Field of Use, (i) under the Patent Rights and the Licensee Patent Rights improvements to make, have made, sell, lease, offer for sale, and import the Licensed Products, and (ii) to use the Licensor Information solely in connection with the Licensed Products.
License Property
Patent Rights PCT/US04/019337 Microparticles for Micro-arterial Imaging and Radiotherapy.

Its intended use is as a means of micro-arterial brachytherapy in the treatment of soft tissue cancer tumors in the liver. Soft tissue tumors are connected to the blood supply and this kind of therapy is administered through the blood supply system. Soft tissue tumors are among the most difficult forms of cancer to treat.

Field of Use
Licensed Field of Use shall mean the human healthcare field.

IPSCIO Record ID: 25940

License Grant
An Australian Company signed a License for the clinical development, marketing and distribution of BrachySil in China. Under the terms of the License, we will manufacture BrachySil and Licensee will be responsible for clinical development, securing regulatory approval, marketing and distribution in China and Hong Kong. We will retain manufacturing rights for BrachySil under the License.
License Property
BrachySil, the company's lead BioSilicon application, is a targeted oncology product, which is presently in Phase II clinical trials for the treatment of both primary liver cancer and pancreatic cancer.

The technology company is about half way through U.S. regulatory testing of its modified silicon product BioSilicon that allows tiny pieces of radioactive material to be directly injected into primary liver tumours, as opposed to traditional radiotherapy that involves hitting a broader area with radiation.

Field of Use
“Licensed Field” 32P BioSilicon microparticles for use as a radiotherapy agent for the treatment or monitoring of solid cancerous tumours, including the primary tumour and metastases, which can be applied

i) interstitially within a cancerous tumour;

ii) into a resection cavity after surgical removal of a cancerous tumour;

iii) into the peritoneal cavity; or

iv) via the vasculature ( to the extent it becomes technically feasible).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.